Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 5:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 209 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo + Methotrexate Clear all
Completed Phase 3 Interventional Results available

Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy

NCT02886728
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Filgotinib, Placebo to match filgotinib, MTX, Placebo to match MTX
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
1,252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
45
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2021 · Synced Oct 26, 2026, 5:47 PM EDT
Completed Not applicable Interventional Results available

Rheumatoid Arthritis: Comparison of Active Therapies in Patients With Active Disease Despite Methotrexate Therapy

NCT00405275
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Etanercept, methotrexate, Sulfasalazine, Hydroxychloroquine, Placebo, triple, Placebo, etanercept
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
28
States / cities
Loma Linda, California • Long Beach, California • San Francisco, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2013 · Synced Oct 26, 2026, 5:47 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Intravenous ACZ885 and Oral Methotrexate Therapy in Patients With Early Rheumatoid Arthritis

NCT00487825
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Canakinumab (investigational), Placebo, Methotrexate (MTX)
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 75 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
17
States / cities
Huntsville, Alabama • Tuscaloosa, Alabama • Paradise Valley, Arizona + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Oct 26, 2026, 5:47 PM EDT
Completed Phase 2 Interventional Results available

Effects of Tofacitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA)

NCT01164579
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tasocitinib plus Methotrexate, Tofacitinib plus placebo methotrexate, Placebo tofacitinib plus Methotrexate
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
8
States / cities
Gilbert, Arizona • Huntington Beach, California • Upland, California + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2015 · Synced Oct 26, 2026, 5:47 PM EDT
Completed Phase 3 Interventional Results available

Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate

NCT02889796
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Filgotinib, Placebo to match filgotinib, Adalimumab, Placebo to match adalimumab, MTX
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
1,759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
48
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 26, 2026, 5:47 PM EDT
Completed Phase 2 Interventional

Safety and Effectiveness Study of RWJ-445380 Cathepsin-S Inhibitor in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy

NCT00425321
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
RWJ-445380 100 mg, RWJ-445380 200 mg, RWJ-445380 300 mg, Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
13
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 10 more
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Oct 26, 2026, 5:47 PM EDT
Terminated Phase 2 Interventional Results available

CD40L Antagonism in Rheumatoid Arthritis (RA)

NCT05306353
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo for VIB4920, VIB4920 with TNFi, VIB4920 without TNFi
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
5
States / cities
San Francisco, California • Aurora, Colorado • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 26, 2026, 5:47 PM EDT
Completed Phase 3 Interventional

A Placebo Controlled Study to Assess Efficacy and Safety of Certolizumab Pegol in the Treatment of Rheumatoid Arthritis

NCT00152386
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Certolizumab pegol (CDP870)
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
950 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
26
States / cities
Huntsville, Alabama • Paradise Valley, Arizona • La Jolla, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2020 · Synced Oct 26, 2026, 5:47 PM EDT
Terminated Phase 2 Interventional Results available

Effect of SAR153191 (REGN88) With Methotrexate in Patients With Active Rheumatoid Arthritis Who Failed TNF-α Blockers

NCT01217814
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Sarilumab, Placebo, Golimumab, methotrexate (MTX), Folic/folinic acid
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Freehold, New Jersey • New York, New York • Jackson, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2017 · Synced Oct 26, 2026, 5:47 PM EDT
Completed Phase 2 Interventional Results available

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

NCT01373151
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
BMS-945429 Placebo, BMS-945429, Methotrexate, Methotrexate Placebo, Adalimumab Placebo, Adalimumab
Drug · Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
13
States / cities
Peoria, Arizona • San Diego, California • Trumbull, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2021 · Synced Oct 26, 2026, 5:47 PM EDT
Completed Phase 3 Interventional Results available

To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)

NCT01709578
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Sarilumab, placebo, hydroxychloroquine, methotrexate, sulfasalazine, leflunomide
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
56
States / cities
Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Oct 26, 2026, 5:47 PM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)

NCT02706951
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Methotrexate, Upadacitinib, Placebo Upadacitinib, Placebo Methotrexate
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
648 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
52
States / cities
Huntsville, Alabama • Mobile, Alabama • Gilbert, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 26, 2026, 5:47 PM EDT
Recruiting Phase 2 Interventional

A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE)

NCT07280156
View directory record Official record
Conditions
Gout
Interventions
PRX-115, Methotrexate (MTX), PRX-115 placebo, Placebo-Methotrexate
Biological · Drug · Other
Lead sponsor
Protalix
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
26
States / cities
Glendale, Arizona • Little Rock, Arkansas • Anaheim, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 26, 2026, 5:47 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis

NCT00298272
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
IDEC-C2B8 (rituximab), Placebo, Methotrexate, Etanercept, Adalimumab, Methylprednisolone, Folate
Biological · Drug · Dietary Supplement
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
18
States / cities
Huntsville, Alabama • Paradise Valley, Arizona • Palm Desert, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2015 · Synced Oct 26, 2026, 5:47 PM EDT
Completed Phase 3 Interventional

Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis

NCT05814627
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Upadacitinib, Adalimumab, Upadacitinib Matching Placebo, Adalimumab Matching Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
487 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
85
States / cities
Flagstaff, Arizona • Glendale, Arizona • Peoria, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 26, 2026, 5:47 PM EDT
Completed Phase 2 Interventional Results available

A Study for Patients With Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy

NCT00785928
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
LY2127399, Placebo
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
6
States / cities
Huntsville, Alabama • Calabasas, California • Upland, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Oct 26, 2026, 5:47 PM EDT
Completed Phase 2 Interventional Results available

Oral CF101 and Methotrexate Treatment in Rheumatoid Arthritis Patients

NCT00280917
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
CF101
Drug
Lead sponsor
Can-Fite BioPharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
5
States / cities
Peoria, Arizona • Albany, New York • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Oct 26, 2026, 5:47 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Effect of Tocilizumab on Markers of Atherogenic Risk in Patients With Moderate to Severe Rheumatoid Arthritis

NCT00535782
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tocilizumab, Placebo, Methotrexate
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
26
States / cities
Anniston, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Oct 26, 2026, 5:47 PM EDT
Completed Phase 2 Interventional Results available

Safety and Effectiveness of Low-Dose Methotrexate for Reducing Inflammation in HIV-Infected Adults on ARV Medications

NCT01949116
View directory record Official record
Conditions
HIV Infections
Interventions
LDMTX, Placebo, Folic acid
Drug · Dietary Supplement
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
40 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 26, 2026, 5:47 PM EDT
Completed Phase 2 Interventional

A Study of P38 Inhibitor (4) Monotherapy in Patients With Active Rheumatoid Arthritis

NCT00303563
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
P38 Inhibitor (4), Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
22
States / cities
Anniston, Alabama • Scottsdale, Arizona • Tucson, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 26, 2026, 5:47 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Cardiovascular Inflammation Reduction Trial - Inflammation Imaging Study

NCT02576067
View directory record Official record
Conditions
Vascular Inflammation, Atherosclerotic Cardiovascular Disease
Interventions
Low dose methotrexate, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Oct 26, 2026, 5:47 PM EDT
Completed Phase 2 Interventional Results available

Efficacy of Methotrexate in Myasthenia Gravis

NCT00814138
View directory record Official record
Conditions
Myasthenia Gravis
Interventions
Methotrexate, Placebo
Drug · Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
15
States / cities
Phoenix, Arizona • Fresno, California • Irvine, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 26, 2016 · Synced Oct 26, 2026, 5:47 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease

NCT02760433
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Olokizumab, Placebo
Drug
Lead sponsor
R-Pharm International, LLC
Industry
Eligibility
18 Years and older
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
50
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • Covina, California + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 26, 2026, 5:47 PM EDT
Completed Phase 2 Interventional Results available

Phase IIb Study of Evobrutinib in Subjects With Rheumatoid Arthritis

NCT03233230
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
M2591 25 mg QD, M2951 75 mg QD, M2951 50 mg BID, Placebo
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
8
States / cities
Phoenix, Arizona • San Leandro, California • DeBary, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2020 · Synced Oct 26, 2026, 5:47 PM EDT